Caprice Resources Limited logo

Caprice Resources Limited (CRS)

Market Closed
- Market Cap
- P/E Ratio
0.8% Div Yield
2,055,332 Volume
- Eps
Earnings results expected in 48 days

Summary

CRS closed Monday higher, an increase of 5.17% from Friday's close, completing a monthly increase of 15.09%. Over the past 12 months, CRS stock gained 221.05%.
CRS pays dividends to its shareholders, with the most recent payment made on 20 hours ago. The next estimated payment will be in In 3 months on Sep 05, 2025 for a total of A$0.2.
The last earnings report, released on Apr 29, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.48%, based on the last three reports. The next scheduled earnings report is due on Jul 23, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track CRS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
This Top Basic Materials Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

This Top Basic Materials Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Zacks | 1 day ago
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (-1.13; p=0.0078) in patients without nasal polyps.

Globenewswire | 3 days ago
Is Carpenter Technology (CRS) Stock Outpacing Its Basic Materials Peers This Year?

Is Carpenter Technology (CRS) Stock Outpacing Its Basic Materials Peers This Year?

Here is how Carpenter Technology (CRS) and Aris Mining Corporation (ARMN) have performed compared to their sector so far this year.

Zacks | 2 weeks ago

Caprice Resources Limited (CRS) FAQ

On which exchange is it traded?

Caprice Resources Limited is listed on NYSE.

What is its stock symbol?

The ticker symbol is CRS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Jul 23, 2025.

Has Caprice Resources Limited ever had a stock split?

Caprice Resources Limited had 0 splits and the recent split was on Nov 16, 2007.

Caprice Resources Limited Profile

Manufacturing - Metal Fabrication Industry
Industrials Sector
Mr. Tony R. Thene CPA CEO
CXA Exchange
US1442851036 ISIN
US Country
4,600 Employees
28 Jan 2025 Last Dividend
16 Nov 2007 Last Split
- IPO Date

Overview

Carpenter Technology Corporation is a leading manufacturer, fabricator, and distributor of specialty metals, serving customers globally across the United States, Europe, the Asia Pacific, Mexico, and Canada. Founded in 1889 and based in Philadelphia, Pennsylvania, Carpenter Technology has built a reputation for innovation and quality in the metals industry. The company operates through two main segments: Specialty Alloys Operations and Performance Engineered Products, catering to a diverse range of markets including aerospace, defense, medical, transportation, energy, industrial, and consumer sectors.

Products and Services

  • Specialty Alloys
  • Includes a wide variety of high-performance materials such as titanium alloys, stainless steels, alloy steels, and tool steels. These alloys are known for their exceptional strength, durability, and resistance to corrosion and heat, making them ideal for critical applications in aerospace, defense, and other technologies.

  • Powder Metals
  • Offers a range of powder metal products designed for high precision, high performance applications. Powder metals are used in manufacturing parts with complex shapes and features, with applications in aerospace, automotive, energy, and medical industries, among others.

  • Additives
  • Carpenter Technology produces various metal-based additive manufacturing powders, designed to enhance the performance and functionality of 3D printed parts. These materials support a broad range of industries, including aerospace, medical, and automotive, by enabling the production of complex geometries that are difficult or impossible to achieve with traditional manufacturing methods.

  • Metal Powders and Parts
  • The company also specializes in the production of metal powders and parts, catering to the specific needs of industries that require high-quality metal components. This includes the production of precision parts for aerospace engines and structures, medical implants, and energy applications, delivering products that meet stringent industry standards.

Contact Information

Address: 1735 Market Street
Phone: 610 208 2000